David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images)
February 2, 2023 03:55 PM ESTUpdated 04:07 PM
Pharma

Eli Lil­ly touts sky­rock­et­ing Moun­jaro pre­scrip­tions even as it re­ports an over­all slump in 2022 rev­enue

Katherine Lewin

News Reporter

Eli Lil­ly is bet­ting big on its type 2 di­a­betes drug Moun­jaro amid sky­rock­et­ing pre­scrip­tions since its launch.

The com­pa­ny ex­pects US net prices to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times